<DOC>
	<DOCNO>NCT00141284</DOCNO>
	<brief_summary>The purpose study confirm safety , efficacy delineate pharmacokinetic property nelfinavir HIV/ Hepatitis C coinfected subject Child Pugh A compensated cirrhosis Hepatic fibrosis</brief_summary>
	<brief_title>An Open Label Study To Evaluate The Safety Kinetics Nelfinavir Subjects With HIV Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>HIV/ Hepatitic C co infect documented HCV viremia evidence cirrhosis hepatic fibrosis liver biopsy , positive fibrosis index , stable health Decompensated cirrhosis ( Child Pugh B C ) Pregnant lactate woman History previous antiretrovirals &gt; 14 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>